Singapore, July 10 -- Japan's JCR Pharmaceuticals Co. has entered into a license agreement with Alexion, AstraZeneca Rare Disease, for JCR's new, proprietary JUST-AAV capsids to develop genomic medicines.
JUST-AAV encompasses a range of vector types optimized for various target tissues-including liver-sparing, muscle-targeting, and brain-targeting variants-to expand the potential of AAV-based gene therapy.
Under the terms of the agreement, Alexion may use the licensed capsids, which are part of the JUST-AAV platform, in up to five of Alexion's genomic medicines programmes.
JCR will receive an upfront payment from Alexion. JCR is eligible to receive milestone payments of up to $225 million related to research and development, and up to ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.